Clinical trial
Effect and Safety of Two Different Dose-escalation Regimens for Once-weekly Semaglutide s.c. in Subjects With Type 2 Diabetes Mellitus Previously Treated With GLP-1 RAs
NCT04287179 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect and Safety of Two Different Dose-escalation Regimens for Once-weekly Semaglutide s.c. in Subjects With Type 2 Diabetes Mellitus Previously Treated With GLP-1 RAs
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- March 9, 2020
- Completion date
- January 25, 2021
- Enrollment
- 0 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.